3 results
Not approvedWill not start
The ATLAS-A/B trial (ALN-AT3SC-004) is a multicenter, multinational, randomized, openlabel Phase 3 study designed to demonstrate the efficacy and safety of fitusiran in patients with hemophilia A or B without inhibitory antibodies to FVIII or FIX…
Approved WMOCompleted
1) To identify T2 low biomarkers and 2) to unravel the mechanisms and downstream effects of Tezepelumab in T2 low asthma.
Approved WMORecruiting
The primary aim of the NOPHO-DBH AML 2012 study is to improve EFS and OS in children with AML. To improve outcome, an intensified induction regimen will be given and a response guided risk-group stratification using flow cytometric minimal residual…